Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure

Pharmacological Reviews

Volumn 71, Issue 4, 2019, Pages 539-570

  Arendse, Lauren B ^a   Jan Danser, A H ^b   Poglitsch, Marko ^c   Touyz, Rhian M ^d   Burnett, John C ^e   Llorens Cortes, Catherine ^f   Ehlers, Mario R ^g   Sturrock, Edward D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Attoquant Diagnostics GmbH   (Austria)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e MAYO CLINIC   (United States)

^f INSERM   (France)

^g Immune Tolerance Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE INHIBITOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR; ANGIOTENSINOGEN; ANTISENSE OLIGONUCLEOTIDE; C DOMAIN SELECTIVE ANGIOTENSIN CONVERTING ENZYME INHIBITOR; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; GLUTAMYL AMINOPEPTIDASE; KININ; MAS RECEPTOR; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; PEPTIDE; PEPTIDE HORMONE; RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTISENSE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; DRUG TARGETING; HEART FAILURE; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASOMOTOR SYSTEM; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PHARMACOLOGY; PHYSIOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; HEART FAILURE; HUMANS; HYPERTENSION; MOLECULAR TARGETED THERAPY; RENIN-ANGIOTENSIN SYSTEM; SMALL MOLECULE LIBRARIES;

EID: 85072401093     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.118.017129     Document Type: Article

References (397)

1. Abassi Z, Karram T, Ellaham S, Winaver J, and Hoffman A (2004) Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 102:223-241.
2. AbdAlla S, Lother H, Abdel-tawab AM, and Quitterer U (2001) The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 276:39721-39726.
3. AbdAlla S, Lother H, and Quitterer U (2000) AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407:94-98.
4. Agah R, Bandi V, and Guntupalli KK (1997) Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med 23:793-796.
5. Akif M, Schwager SL, Anthony CS, Czarny B, Beau F, Dive V, Sturrock ED, and Acharya KR (2011) Novel mechanism of inhibition of human angiotensin-Iconverting enzyme (ACE) by a highly specific phosphinic tripeptide. Biochem J 436:53-59.
6. Almquist RG, Chao WR, Ellis ME, and Johnson HL (1980) Synthesis and biological activity of a ketomethylene analogue of a tripeptide inhibitor of angiotensin converting enzyme. J Med Chem 23:1392-1398.
7. Ambroz C, Clark AJ, and Catt KJ (1991) The mas oncogene enhances angiotensininduced [Ca21]i responses in cells with pre-existing angiotensin II receptors. Biochim Biophys Acta 1133:107-111.
8. Ando S, Rahman MA, Butler GC, Senn BL, and Floras JS (1995) Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 26:1160-1166.
9. Atlas SA (2007) The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 13 (Suppl B):9-20.
10. Azizi M, Bissery A, Peyrard S, Guyene TT, Ozoux ML, Floch A, and Ménard J (2006) Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. Clin Pharmacol Ther 79:49-61.
11. Azizi M, Courand P, Denolle T, Zhygalina V, Delsart P, Amar L, Lantelme P, Deplanque D, Mounier-Vehier C, and Balavoine F (2017) [OP. 4A. 08] A randomized double-blind placebo controlled crossover study to compare QGC001, a brain aminopeptidase A inhibitor, with placebo in patients with grade I/II essential hypertension (Abstract). J Hypertens 35:e36.
12. Azizi M, Ezan E, Reny JL, Wdzieczak-Bakala J, Gerineau V, and Ménard J (1999) Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. Hypertension 33:879-886.
13. Bader M, Alenina N, Andrade-Navarro MA, and Santos RA (2014) MAS and its related G protein-coupled receptors, Mrgprs. Pharmacol Rev 66:1080-1105.
14. Bader M, Alenina N, Young D, Santos RAS, and Touyz RM (2018) The meaning of Mas. Hypertension 72:1072-1075.
15. Bai HY, Mogi M, Nakaoka H, Kan-No H, Tsukuda K, Chisaka T, Wang XL, Kukida M, Shan BS, Yamauchi T, et al. (2015) Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage. Eur J Pharmacol 762:293-298.
16. Balavoine F, Azizi M, Bergerot D, De Mota N, Patouret R, Roques BP, and Llorens-Cortes C (2014) Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase A inhibitor prodrug. Clin Pharmacokinet 53:385-395.
17. Balcarek J, Sevá Pessôa B, Bryson C, Azizi M, Ménard J, Garrelds IM, McGeehan G, Reeves RA, Griffith SG, Danser AHJ, et al. (2014) Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition. Hypertension 63:942-950.
18. Barton M, Shaw S, D’Uscio LV, Moreau P, and Lüscher TF (1997) Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 238:861-865.
19. Bas M (2017) The angiotensin-converting-enzyme-induced angioedema. Immunol Allergy Clin North Am 37:183-200.
20. Bas, M, Greve J, Stelter K, Havel M, Strassen U, Rotter N, Veit J, Schossow B, Hapfelmeier A, Kehl V, et al. (2015) A randomized trial of icatibant in ACEinhibitor-induced angioedema. N Engl J Med 372:418-425.
21. Basso N, Ruiz P, Mangiarua E, and Taquini AC (1981) Renin-like activity in the rat brain during the development of DOC-salt hypertension. Hypertension 3: II-14-II-17.
22. Basu R, Poglitsch M, Yogasundaram H, Thomas J, Rowe BH, and Oudit GY (2017) Roles of angiotensin peptides and recombinant human ACE2 in heart failure. J Am Coll Cardiol 69:805-819.
23. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2017) Heart disease and stroke statistics-2017 update: a report from the American Heart Association [published correction appears in Circulation (2017) 135:e646 and 136:e196]. Circulation 135: e146-e603.
24. Benzing T, Fleming I, Blaukat A, Müller-Esterl W, and Busse R (1999) Angiotensinconverting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 99:2034-2040.
25. Bernstein KE, Ong FS, Blackwell WL, Shah KH, Giani JF, Gonzalez-Villalobos RA, Shen XZ, Fuchs S, and Touyz RM (2012) A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev 65:1-46.
26. Bernstein KE, Shen XZ, Gonzalez-Villalobos RA, Billet S, Okwan-Duodu D, Ong FS, and Fuchs S (2011) Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr Opin Pharmacol 11:105-111.
27. Bodineau L, Frugière A, Marc Y, Inguimbert N, Fassot C, Balavoine F, Roques B, and Llorens-Cortes C (2008) Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 51:1318-1325.
28. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessì-Fulgheri P, Zhang C, Takahashi N, Sarzani R, and Collins S (2012) Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 122:1022-1036.
29. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, and Widdop RE (2011) Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 121:297-303.
30. Bremnes T, Paasche JD, Mehlum A, Sandberg C, Bremnes B, and Attramadal H (2000) Regulation and intracellular trafficking pathways of the endothelin receptors. J Biol Chem 275:17596-17604.
31. Bur D, Dale GE, and Oefner C (2001) A three-dimensional model of endothelinconverting enzyme (ECE) based on the X-ray structure of neutral endopeptidase 24.11 (NEP). Protein Eng 14:337-341.
32. Burger D, Reudelhuber TL, Mahajan A, Chibale K, Sturrock ED, and Touyz RM (2014) Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension. Clin Sci (Lond) 127:57-63.
33. Campbell DJ (2017) Long-term neprilysin inhibition-implications for ARNIs. Nat Rev Cardiol 14:171-186.
34. Campbell DJ and Habener JF (1986) Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest 78:31-39.
35. Cannon JA, Shen L, Jhund PS, Kristensen SL, Køber L, Chen F, Gong J, Lefkowitz MP, Rouleau JL, Shi VC, et al.; PARADIGM-HF Investigators and Committees (2017) Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail 19:129-137.
36. Cataliotti A, Tonne JM, Bellavia D, Martin FL, Oehler EA, Harders GE, Campbell JM, Peng KW, Russell SJ, Malatino LS, et al. (2011) Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation 123:1297-1305.
37. Chappell MC, Pirro NT, Sykes A, and Ferrario CM (1998) Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 31:362-367.
38. Chappell MC, Tallant EA, Brosnihan KB, and Ferrario CM (1995) Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3.4. 24.15) in vascular smooth muscle cells. J Vasc Med Biol 5:129-137.
39. Charles CJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG, Protter A, and Kosoglou T (1996) Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 271:R373-R380.
40. Chauvel EN, Llorens-Cortès C, Coric P, Wilk S, Roques BP, and Fournié-Zaluski MC (1994) Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols. J Med Chem 37:2950-2957.
41. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, and Burnett JC Jr (2012) Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol 60:2305-2312.
42. Chen Y, Harty GJ, Huntley BK, Iyer SR, Heublein DM, Harders GE, Meems L, Pan S, Sangaralingham SJ, Ichiki T, et al. (2018) CRRL269: a novel designer and renal-enhancing pGC-A peptide activator. Am J Physiol Regul Integr Comp Physiol 314:R407-R414.
43. Claperon C, Rozenfeld R, Iturrioz X, Inguimbert N, Okada M, Roques B, Maigret B, and Llorens-Cortes C (2008) Asp218 participates with Asp213 to bind a Ca21 atom into the S1 subsite of aminopeptidase A: a key element for substrate specificity. Biochem J 416:37-46.
44. Cleland JG and Swedberg K; The International Ecadotril Multi-centre Dose-ranging Study Investigators (1998) Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. Lancet 351:1657-1658.
45. Coats AJ (2002) Omapatrilat--the story of Overture and Octave. Int J Cardiol 86:1-4.
46. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, Shaknovich A, Pondolfino K, Clark M, Camargo MJ, et al. (1986) Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 78:1362-1374.
47. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, et al.; Nesiritide Study Group (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343:246-253.
48. Cook VI, Grove KL, McMenamin KM, Carter MR, Harding JW, and Speth RC (1991) The AT2 angiotensin receptor subtype predominates in the 18 day gestation fetal rat brain. Brain Res 560:334-336.
49. Corradi HR, Chitapi I, Sewell BT, Georgiadis D, Dive V, Sturrock ED, and Acharya KR (2007) The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. Biochemistry 46:5473-5478.
50. Corradi HR, Schwager SL, Nchinda AT, Sturrock ED, and Acharya KR (2006) Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J Mol Biol 357:964-974.
51. Cotton J, Hayashi MA, Cuniasse P, Vazeux G, Ianzer D, De Camargo AC, and Dive V (2002) Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides. Biochemistry 41:6065-6071.
52. Cozier GE, Arendse LB, Schwager SL, Sturrock ED, and Acharya KR (2018) Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain. J Med Chem 61(22):10141-10154.
53. Cushman DW, Cheung HS, Sabo EF, and Ondetti MA (1977) Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16:5484-5491.
54. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, et al.; LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003.
55. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, et al. (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 6:489-498.
56. Danilczyk U, Sarao R, Remy C, Benabbas C, Stange G, Richter A, Arya S, Pospisilik JA, Singer D, Camargo SM, et al. (2006) Essential role for collectrin in renal amino acid transport. Nature 444:1088-1091.
57. Danser AHJ, Batenburg WW, van den Meiracker AH, and Danilov SM (2007) ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition? Pharmacol Ther 113:607-618.
58. Danser AHJ, Derkx FH, Hense HW, Jeunemaître X, Riegger GA, and Schunkert H (1998) Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels. J Hypertens 16:1879-1883.
59. Danser AHJ, van Kesteren CA, Bax WA, Tavenier M, Derkx FH, Saxena PR, and Schalekamp MA (1997) Prorenin, renin, angiotensinogen, and angiotensinconverting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 96:220-226.
60. Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, Beaudoin M, Belleville K, Sirois P, Nantel F, et al. (2005) Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens 18:1606-1613.
61. Daull P, Blouin A, Belleville K, Beaudoin M, Arsenault D, Leonard H, Sirois P, Nantel F, Jeng AY, and Battistini B (2006b) Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats. Exp Biol Med (Maywood) 231:830-833.
62. Daull P, Lepage R, Benrezzak O, Cayer J, Beaudoin M, Belleville K, Blouin A, Sirois P, Nantel F, Jeng AY, et al. (2006a) The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats. Drug Chem Toxicol 29:183-202.
63. David C, Bischoff L, Meudal H, Mothé A, De Mota N, DaNascimento S, Llorens-Cortes C, Fournié-Zaluski MC, and Roques BP (1999) Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme. J Med Chem 42:5197-5211.
64. Davis JO and Freeman RH (1976) Mechanisms regulating renin release. Physiol Rev 56:1-56.
65. Davisson RL, Yang G, Beltz TG, Cassell MD, Johnson AK, and Sigmund CD (1998) The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes. Circ Res 83:1047-1058.
66. de Bold AJ, de Bold ML, and Sarda IR (1986) Functional-morphological studies on in vitro cardionatrin release. J Hypertens Suppl 4:S3-S7.
67. de Gasparo M, Catt KJ, Inagami T, Wright JW, and Unger T (2000) International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415-472.
68. de Lannoy LM, Danser AHJ, van Kats JP, Schoemaker RG, Saxena PR, and Schalekamp MA (1997) Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 29:1240-1251.
69. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, and Erdös EG (1998) N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension 31:912-917.
70. Denault JB, Claing A, D’Orléans-Juste P, Sawamura T, Kido T, Masaki T, and Leduc R (1995) Processing of proendothelin-1 by human furin convertase. FEBS Lett 362:276-280.
71. Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R, and Koopman PA (2004) Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 94:237-239.
72. Dimitropoulos N, Papakyriakou A, Dalkas GA, Sturrock ED, and Spyroulias GA (2010) A computational approach to the study of the binding mode of dual ACE/NEP inhibitors. J Chem Inf Model 50:388-396.
73. Dive V, Cotton J, Yiotakis A, Michaud A, Vassiliou S, Jiracek J, Vazeux G, Chauvet MT, Cuniasse P, and Corvol P (1999) RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc Natl Acad Sci USA 96:4330-4335.
74. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, et al. (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87:E1-E9.
75. Douglas RG, Sharma RK, Masuyer G, Lubbe L, Zamora I, Acharya KR, Chibale K, and Sturrock ED (2014) Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors. Clin Sci (Lond) 126:305-313.
76. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, and Burnett JC Jr (1988) Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 62:191-195.
77. Ehlers MR, Schwager SL, Scholle RR, Manji GA, Brandt WF, and Riordan JF (1996) Proteolytic release of membrane-bound angiotensin-converting enzyme: role of the juxtamembrane stalk sequence. Biochemistry 35:9549-9559.
78. Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL, and Tang WH (2009) Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 15:565-571.
79. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, and Sen S (2008) Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 52:750-754.
80. Erdös EG and Skidgel RA (1989) Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 3:145-151.
81. Fagyas M, Úri K, Siket IM, Fülöp G, Csató V, Daragó A, Boczán J, Bányai E, Szentkirályi IE, Maros TM, et al. (2014) New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human. PLoS One 9:e87844.
82. Fattah C, Nather K, McCarroll CS, Hortigon-Vinagre MP, Zamora V, Flores-Munoz M, McArthur L, Zentilin L, Giacca M, Touyz RM, et al. (2016) Gene therapy with angiotensin-(1-9) preserves left ventricular systolic function after myocardial infarction. J Am Coll Cardiol 68:2652-2666.
83. Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, and Brunner HR (1995) Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 13:797-804.
84. Ferdinand K, Balavoine F, Besse B, Black H, Desbrandes S, Dittrich H, and Nesbitt S (2018) Efficacy and safety of a novel antihypertensive pharmacotherapy approach in a high-risk diverse population (Abstract). Circulation 138:e766-e767.
85. Ferrario CM and Mullick AE (2017) Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res 125:57-71.
86. Ferreira PM, Souza Dos Santos RA, and Campagnole-Santos MJ (2007) Angiotensin-(3-7) pressor effect at the rostral ventrolateral medulla. Regul Pept 141:168-174.
87. Ferro CJ, Spratt JC, Haynes WG, and Webb DJ (1998) Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 97:2323-2330.
88. Fienberg S, Cozier GE, Acharya KR, Chibale K, and Sturrock ED (2018) The design and development of a potent and selective novel diprolyl derivative that binds to the N-domain of angiotensin-I converting enzyme. J Med Chem 61:344-359.
89. Fitzgibbon WR, Dang Y, Bunni MA, Baicu CF, Zile MR, Mullick AE, and Saigusa T (2018) Attenuation of accelerated renal cystogenesis in Pkd1 mice by reninangiotensin system blockade. Am J Physiol Renal Physiol 314:F210-F218.
90. Flores-Muñoz M, Smith NJ, Haggerty C, Milligan G, and Nicklin SA (2011) Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol 589:939-951.
91. Flores-Muñoz M, Work LM, Douglas K, Denby L, Dominiczak AF, Graham D, and Nicklin SA (2012) Angiotensin-(1-9) attenuates cardiac fibrosis in the strokeprone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension 59:300-307.
92. Fonarow GC, Hernandez AF, Solomon SD, and Yancy CW (2016) Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure. JAMA Cardiol 1:714-717.
93. Fournié-Zaluski MC, Coric P, Turcaud S, Bruetschy L, Lucas E, Noble F, and Roques BP (1992) Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation. J Med Chem 35:1259-1266.
94. Fournie-Zaluski MC, Fassot C, Valentin B, Djordjijevic D, Reaux-Le Goazigo A, Corvol P, Roques BP, and Llorens-Cortes C (2004) Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension. Proc Natl Acad Sci USA 101:7775-7780.
95. Fox AJ, Lalloo UG, Belvisi MG, Bernareggi M, Chung KF, and Barnes PJ (1996) Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med 2:814-817.
96. Fraga-Silva RA, Pinheiro SVB, Gonçalves ACC, Alenina N, Bader M, and Santos RAS (2008) The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med 14:28-35.
97. Fryer RM, Segreti J, Banfor PN, Widomski DL, Backes BJ, Lin CW, Ballaron SJ, Cox BF, Trevillyan JM, Reinhart GA, et al. (2008) Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 153:947-955.
98. Fuchs S, Xiao HD, Cole JM, Adams JW, Frenzel K, Michaud A, Zhao H, Keshelava G, Capecchi MR, Corvol P, et al. (2004) Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem 279:15946-15953.
99. Fuchs S, Xiao HD, Hubert C, Michaud A, Campbell DJ, Adams JW, Capecchi MR, Corvol P, and Bernstein KE (2008) Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51:267-274.
100. Gaidarov I, Adams J, Frazer J, Anthony T, Chen X, Gatlin J, Semple G, and Unett DJ (2018) Angiotensin (1-7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor. Cell Signal 50:9-24.
101. Galandrin S, Denis C, Boularan C, Marie J, M’Kadmi C, Pilette C, Dubroca C, Nicaise Y, Seguelas MH, N’Guyen D, et al. (2016) Cardioprotective angiotensin-(1-7) peptide acts as a natural-biased ligand at the angiotensin II type 1 receptor. Hypertension 68:1365-1374.
102. Ganten D, Hermann K, Bayer C, Unger T, and Lang RE (1983) Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science 221:869-871.
103. Gembardt F, Grajewski S, Vahl M, Schultheiss HP, and Walther T (2008) Angiotensin metabolites can stimulate receptors of the Mas-related genes family. Mol Cell Biochem 319:115-123.
104. Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, and Dive V (2003) Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res 93:148-154.
105. Gjymishka A, Kulemina LV, Shenoy V, Katovich MJ, Ostrov DA, and Raizada MK (2010) Diminazene aceturate is an ACE2 activator and a novel antihypertensive drug. FASEB J 24:1032.3.
106. Glenner GG, McMILLAN PJ, and Folk JE (1962) A mammalian peptidase specific for the hydrolysis of N-terminal a-L-glutamyl and aspartyl residues. Nature 194:867.
107. Glossop MS, Bazin RJ, Dack KN, Fox DN, MacDonald GA, Mills M, Owen DR, Phillips C, Reeves KA, Ringer TJ, et al. (2011) Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral endopeptidase inhibitors. Bioorg Med Chem Lett 21:3404-3406.
108. Goto Y, Hattori A, Mizutani S, and Tsujimoto M (2007) Asparatic acid 221 is critical in the calcium-induced modulation of the enzymatic activity of human aminopeptidase A. J Biol Chem 282:37074-37081.
109. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Östergren J, Pfeffer MA, and Swedberg K; CHARM Investigators and Committees (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772-776.
110. Grobe JL, Der Sarkissian S, Stewart JM, Meszaros JG, Raizada MK, and Katovich MJ (2007) ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond) 113:357-364.
111. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, et al. (2010) Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 50:401-414.
112. Guimarães PB, Alvarenga EC, Siqueira PD, Paredes-Gamero EJ, Sabatini RA, Morais RL, Reis RI, Santos EL, Teixeira LG, Casarini DE, et al. (2011) Angiotensin II binding to angiotensin I-converting enzyme triggers calcium signaling. Hypertension 57:965-972.
113. Gyurko R, Wielbo D, and Phillips MI (1993) Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pept 49:167-174.
114. Hagiwara H, Sakaguchi H, Itakura M, Yoshimoto T, Furuya M, Tanaka S, and Hirose S (1994) Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B. J Biol Chem 269:10729-10733.
115. Hansen JL, Theilade J, Haunsø S, and Sheikh SP (2004) Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling but not ERK activation. J Biol Chem 279:24108-24115.
116. Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, and Krähenbühl S (2013) Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 52:783-792.
117. Hashimoto Y, Nakao K, Hama N, Imura H, Mori S, Yamaguchi M, Yasuhara M, and Hori R (1994) Clearance mechanisms of atrial and brain natriuretic peptides in rats. Pharm Res 11:60-64.
118. Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, Yokoyama H, Tanaka K, Mizuno K, Nejima J, et al. (2008) Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J 72:1787-1793.
119. Hawkridge AM, Heublein DM, Bergen HR 3rd, Cataliotti A, Burnett JC Jr, and Muddiman DC (2005) Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 102:17442-17447.
120. Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, et al. (2018) Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation 138:1505-1514.
121. Healy DP and Wilk S (1993) Localization of immunoreactive glutamyl aminopeptidase in rat brain. II. Distribution and correlation with angiotensin II. Brain Res 606:295-303.
122. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, et al. (2008) Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 51:1312-1317.
123. Hoang MV and Turner AJ (1997) Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem J 327:23-26.
124. Huang BS, Ahmad M, White RA, Marc Y, Llorens-Cortes C, and Leenen FH (2013) Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction. Cardiovasc Res 97:424-431.
125. Ichiki T, Kambayashi Y, and Inagami T (1995) Multiple growth factors modulate mRNA expression of angiotensin II type-2 receptor in R3T3 cells. Circ Res 77:1070-1076.
126. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, and Marumo F (1992) Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 19:753-757.
127. Intengan HD and Schiffrin EL (2000) Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension 35:1221-1225.
128. Israili ZH and Hall WD (1992) Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 117:234-242.
129. Itoh Y, Yanagisawa M, Ohkubo S, Kimura C, Kosaka T, Inoue A, Ishida N, Mitsui Y, Onda H, Fujino M, et al. (1988) Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin. FEBS Lett 231:440-444.
130. Iusuf D, Henning RH, van Gilst WH, and Roks AJ (2008) Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 585:303-312.
131. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, and Saido TC (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292:1550-1552.
132. Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, Marcic BM, and Erdös EG (2002) Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension 39:976-981.
133. Jackson TR, Blair LA, Marshall J, Goedert M, and Hanley MR (1988) The mas oncogene encodes an angiotensin receptor. Nature 335:437-440.
134. Jandeleit-Dahm KA (2006) Dual ACE/NEP inhibitors-more than playing the ACE card. J Hum Hypertens 20:478-481.
135. Jankowski V, Tölle M, Santos RA, Günthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SVB, Sampaio WO, et al. (2011) Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J 25:2987-2995.
136. Jarcho J (2019) PIONEERing the in-hospital initiation of sacubitril-valsartan. N Engl J Med 380:590-591.
137. Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, Liu FF, Zhang K, and Zhang C (2014) Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol 11:413-426.
138. Johnson AG, Pearce GL, and Danoff TM (2006) A randomized, double-blind, placebocontrolled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients. J Hum Hypertens 20:496-503.
139. Jullien N, Makritis A, Georgiadis D, Beau F, Yiotakis A, and Dive V (2010) Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem 53:208-220.
140. Junot C, Gonzales MF, Ezan E, Cotton J, Vazeux G, Michaud A, Azizi M, Vassiliou S, Yiotakis A, Corvol P, et al. (2001) RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J Pharmacol Exp Ther 297:606-611.
141. Kakoki M and Smithies O (2009) The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int 75:1019-1030.
142. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, and Inagami T (1993) Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 268:24543-24546.
143. Kambayashi Y, Nagata K, Ichiki T, and Inagami T (1996) Insulin and insulin-like growth factors induce expression of angiotensin type-2 receptor in vascularsmooth-muscle cells. Eur J Biochem 239:558-565.
144. Kang J, Posner P, and Sumners C (1994) Angiotensin II type 2 receptor stimulation of neuronal K1 currents involves an inhibitory GTP binding protein. Am J Physiol 267:C1389-C1397.
145. Kang J, Richards EM, Posner P, and Sumners C (1995) Modulation of the delayed rectifier K1 current in neurons by an angiotensin II type 2 receptor fragment. Am J Physiol 268:C278-C282.
146. Karnik SS, Singh KD, Tirupula K, and Unal H (2017) Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22. Br J Pharmacol 174:737-753.
147. Karnik SS, Unal H, Kemp JR, Tirupula KC, Eguchi S, Vanderheyden PM, and Thomas WG (2015) International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [published correction appears in Pharmacol Rev (2015) 67:820]. Pharmacol Rev 67:754-819.
148. Kedzierski RM and Yanagisawa M (2001) Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41:851-876.
149. Kerr MA and Kenny AJ (1974) The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 137:477-488.
150. Khan BA, Perkins AJ, Gao S, Hui SL, Campbell NL, Farber MO, Chlan LL, and Boustani MA (2017) The confusion assessment method for the ICU-7 delirium severity scale: a novel delirium severity instrument for use in the ICU. Crit Care Med 45:851-857.
151. Kijima K, Matsubara H, Murasawa S, Maruyama K, Ohkubo N, Mori Y, and Inada M (1996) Regulation of angiotensin II type 2 receptor gene by the protein kinase C-calcium pathway. Hypertension 27:529-534.
152. Kimura S, Kasuya Y, Sawamura T, Shinimi O, Sugita Y, Yanagisawa M, Goto K, and Masaki T (1989) Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure-activity relationships of big endothelin-1. J Cardiovasc Pharmacol 13 (Suppl 5):S5-S7, discussion S18.
153. Kleniewski J (1979) Plasma high molecular weight kininogen concentration in health and in chosen impairments of haemostasis. Evidence that plasmin uncovers a new antigenic site in high molecular weight kininogen. Thromb Haemost 42:1046-1055.
154. Klotz S, Burkhoff D, Garrelds IM, Boomsma F, and Danser AHJ (2009) The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences? Eur Heart J 30:805-812.
155. Komers R, Gipson DS, Nelson P, Adler S, Srivastava T, Derebail VK, Meyers KE, Pergola P, MacNally ME, Hunt JL, et al. (2017) Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET). Kidney Int Rep 2:654-664.
156. Komers R and Plotkin H (2016) Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 310:R877-R884.
157. Kompa AR, Lu J, Weller TJ, Kelly DJ, Krum H, von Lueder TG, and Wang BH (2018) Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction. Int J Cardiol 258:192-198.
158. Korth P, Bohle RM, Corvol P, and Pinet F (1999) Cellular distribution of endothelinconverting enzyme-1 in human tissues. J Histochem Cytochem 47:447-462.
159. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, et al. (2005) G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111:1806-1813.
160. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, and Levy E (2004) Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 17:103-111.
161. Kostis WJ, Shetty M, Chowdhury YS, and Kostis JB (2018) ACE inhibitor-induced angioedema: a review. Curr Hypertens Rep 20:55.
162. Kowalczuk S, Bröer A, Tietze N, Vanslambrouck JM, Rasko JE, and Bröer S (2008) A protein complex in the brush-border membrane explains a Hartnup disorder allele. FASEB J 22:2880-2887.
163. Kröger WL, Douglas RG, O’Neill HG, Dive V, and Sturrock ED (2009) Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme. Biochemistry 48:8405-8412.
164. Kuhn M (2016) Molecular physiology of membrane guanylyl cyclase receptors. Physiol Rev 96:751-804.
165. Kukkola PJ, Savage P, Sakane Y, Berry JC, Bilci NA, Ghai RD, and Jeng AY (1995) Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 26(Suppl 3):S65-S68.
166. Kuoppala A, Lindstedt KA, Saarinen J, Kovanen PT, and Kokkonen JO (2000) Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am J Physiol Heart Circ Physiol 278:H1069-H1074.
167. Lachance D, Garcia R, Gutkowska J, Cantin M, and Thibault G (1986) Mechanisms of release of atrial natriuretic factor. I. Effect of several agonists and steroids on its release by atrial minces. Biochem Biophys Res Commun 135:1090-1098.
168. Lalmanach G, Naudin C, Lecaille F, and Fritz H (2010) Kininogens: more than cysteine protease inhibitors and kinin precursors. Biochimie 92:1568-1579.
169. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, and Turner AJ (2005) Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndromecoronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280:30113-30119.
170. Langenickel TH, Tsubouchi C, Ayalasomayajula S, Pal P, Valentin MA, Hinder M, Jhee S, Gevorkyan H, and Rajman I (2016) The effect of LCZ696 (sacubitril/valsartan) on amyloid-b concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol 81:878-890.
171. Lapointe N and Rouleau JL (2002) Cardioprotective effects of vasopeptidase inhibitors. Can J Cardiol 18:415-420.
172. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, Sousa F, Alzamora A, et al. (2013) Discovery and characterization of alamandine: a novel component of the renin-angiotensin system [published correction appears in Circ Res (2013) 112:e156]. Circ Res 112:1104-1111.
173. Leal MC, Pinheiro SV, Ferreira AJ, Santos RA, Bordoni LS, Alenina N, Bader M, and França LR (2009) The role of angiotensin-(1-7) receptor Mas in spermatogenesis in mice and rats. J Anat 214:736-743.
174. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, and Zuraw BL (2005) International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57:27-77.
175. Lejczak B, De Choszczak MP, and Kafarski P (1993) Inhibition of aminopeptidases by phosphonic acid and phosphinic acid analogues of aspartic and glutamic acids. J Enzyme Inhib 7:97-103.
176. Lenkei Z, Palkovits M, Corvol P, and Llorens-Cortès C (1997) Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol 18:383-439.
177. Levin AA (2019) Treating disease at the RNA level with oligonucleotides. N Engl J Med 380:57-70.
178. Li F, Li W, Farzan M, and Harrison SC (2005) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309:1864-1868.
179. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450-454.
180. Liu GC, Oudit GY, Fang F, Zhou J, and Scholey JW (2012) Angiotensin-(1-7)-induced activation of ERK1/2 is cAMP/protein kinase A-dependent in glomerular mesangial cells. Am J Physiol Renal Physiol 302:F784-F790.
181. Llorens C, Gacel G, Swerts JP, Perdrisot R, Fournie-Zaluski MC, Schwartz JC, and Roques BP (1980) Rational design of enkephalinase inhibitors: substrate specificity of enkephalinase studied from inhibitory potency of various dipeptides. Biochem Biophys Res Commun 96:1710-1716. Lojda Z and Gossrau R (1980) Study on aminopeptidase A. Histochemistry 67:267-290.
182. Lombard-Banek C, Yu Z, Swiercz AP, Marvar PJ, and Nemes P (2019) A microanalytical capillary electrophoresis mass spectrometry assay for quantifying angiotensin peptides in the brain. Anal Bioanal Chem 411:4661-4671.
183. Lopez Verrilli MA, Rodriguez Fermepín M, Longo Carbajosa N, Landa S, Cerrato BD, García S, Fernandez BE, and Gironacci MM (2012) Angiotensin-(1-7) through Mas receptor up-regulates neuronal norepinephrine transporter via Akt and Erk1/2- dependent pathways. J Neurochem 120:46-55.
184. Ma L, Li J, Wang G, Gong S, Zhang L, Li K, Ji X, Liu Y, Chen P, and Xiang X (2013) Atrial natriuretic peptide suppresses Th17 development through regulation of cGMP-dependent protein kinase and PI3K-Akt signaling pathways. Regul Pept 181:9-16.
185. Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, Mangiafico S, Ikeda Y, Bailey K, Scott CG, et al. (2012) Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol 60:1558-1565.
186. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, et al.; Breathing Not Properly Multinational Study Investigators (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161-167.
187. Malek V, Sharma N, Sankrityayan H, and Gaikwad AB (2019) Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy. Life Sci 221:159-167.
188. Malfroy B, Swerts JP, Guyon A, Roques BP, and Schwartz JC (1978) High-affinity enkephalin-degrading peptidase in brain is increased after morphine. Nature 276:523-526.
189. Marc Y, Gao J, Balavoine F, Michaud A, Roques BP, and Llorens-Cortes C (2012) Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. Hypertension 60:411-418.
190. Marc Y, Hmazzou R, Balavoine F, Flahault A, and Llorens-Cortes C (2018) Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats. J Hypertens 36:641-650.
191. Marcic B, Deddish PA, Jackman HL, and Erdös EG (1999) Enhancement of bradykinin and resensitization of its B2 receptor. Hypertension 33:835-843.
192. Masuyer G, Akif M, Czary B, Beau F, Schwager SL, Sturrock ED, Isaac RE, Dive V, and Acharya KR (2014) Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme. FEBS J 281 (3): 943-956.
193. Masuyer G, Schwager SL, Sturrock ED, Isaac RE, and Acharya KR (2012) Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Sci Rep 2:717.
194. Matsusaka T, Niimura F, Pastan I, Shintani A, Nishiyama A, and Ichikawa I (2014) Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation. Kidney Int 85:1068-1077.
195. Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, Nishiyama A, and Ichikawa I (2012) Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol 23:1181-1189.
196. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, et al.; PARADIGM-HF Committees and Investigators (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15:1062-1073.
197. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al.; PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993-1004.
198. Meems LMG, Andersen IA, Pan S, Harty G, Chen Y, Zheng Y, Harders GE, Ichiki T, Heublein DM, Iyer SR, et al. (2019) Design, synthesis, and actions of an innovative bispecific designer peptide. Hypertension 73:900-909.
199. Meems LMG and Burnett JC Jr (2016) Innovative therapeutics: designer natriuretic peptides. JACC Basic Transl Sci 1:557-567.
200. Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Piña IL, Fiuzat M, et al. (2013) The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol 167:1677-1687.
201. Migaud M, Durieux C, Viereck J, Soroca-Lucas E, Fournié-Zaluski MC, and Roques BP (1996) The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A. Peptides 17:601-607.
202. Millan MA, Jacobowitz DM, Aguilera G, and Catt KJ (1991) Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development. Proc Natl Acad Sci USA 88:11440-11444.
203. Mogensen UM, Gong J, Jhund PS, Shen L, Køber L, Desai AS, Lefkowitz MP, Packer M, Rouleau JL, Solomon SD, et al. (2018) Effect of sacubitril/valsartan on recurrent events in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 20:760-768.
204. Molinaro G, Cugno M, Perez M, Lepage Y, Gervais N, Agostoni A, and Adam A (2002) Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther 303:232-237.
205. Mori J, Patel VB, Abo Alrob O, Basu R, Altamimi T, Desaulniers J, Wagg CS, Kassiri Z, Lopaschuk GD, and Oudit GY (2014) Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail 7:327-339.
206. Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, and Braunwald E (2019) Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J [published ahead of print].
207. Motte S, McEntee K, and Naeije R (2006) Endothelin receptor antagonists. Pharmacol Ther 110:386-414.
208. Moukarbel GV and Solomon SD (2008) Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: evidence from clinical trials. Curr Heart Fail Rep 5:197-203.
209. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, et al. (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87:1402-1412.
210. Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP, and Crooke RM (2017) Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury. Hypertension 70:566-576.
211. Murphy TJ, Alexander RW, Griendling KK, Runge MS, and Bernstein KE (1991) Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351:233-236.
212. Murugesan N, Gu Z, Fadnis L, Tellew JE, Baska RAF, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Valentine MT, et al. (2005) Dual angiotensin II and endothelin A receptor antagonists: synthesis of 29-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem 48:171-179.
213. Murugesan N, Tellew JE, Gu Z, Kunst BL, Fadnis L, Cornelius LA, Baska RAF, Yang Y, Beyer SM, Monshizadegan H, et al. (2002) Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J Med Chem 45:3829-3835.
214. Naftilan AJ and Oparil S (1978) Inhibition of renin release from rat kidney slices by the angiotensins. Am J Physiol 235:F62-F68.
215. Nagatsu I, Nagatsu T, Yamamoto T, Glenner GG, and Mehl JW (1970) Purification of aminopeptidase A in human serum and degradation of angiotensin II by the purified enzyme. Biochim Biophys Acta 198:255-270.
216. Namkung Y, Le Gouill C, Lukashova V, Kobayashi H, Hogue M, Khoury E, Song M, Bouvier M, and Laporte SA (2016) Monitoring G protein-coupled receptor and b-arrestin trafficking in live cells using enhanced bystander BRET. Nat Commun 7:12178.
217. Namsolleck P, Recarti C, Foulquier S, Steckelings UM, and Unger T (2014) AT(2) receptor and tissue injury: therapeutic implications. Curr Hypertens Rep 16:416.
218. Natesh R, Schwager SL, Sturrock ED, and Acharya KR (2003) Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 421:551-554.
219. Nawarskas J, Rajan V, and Frishman WH (2001) Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Heart Dis 3:378-385.
220. Nchinda AT, Chibale K, Redelinghuys P, and Sturrock ED (2006a) Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme. Bioorg Med Chem Lett 16:4616-4619.
221. Nchinda AT, Chibale K, Redelinghuys P, and Sturrock ED (2006b) Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors. Bioorg Med Chem Lett 16:4612-4615.
222. Neutel JM, Germino WF, Punzi H, McBride M, Bryson CC, and Belder R (2008) Results of a double blind placebo controlled study to evaluate the efficacy and safety of PS433540 in human subjects with hypertension (Abstract). Circulation 118 (Suppl 18):S886.
223. OcaranzaMP, Lavandero S, Jalil JE, Moya J, Pinto M, Novoa U, Apablaza F, González L, Hernández C, Varas M, et al. (2010) Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens 28:1054-1064.
224. Ocaranza MP, Moya J, Barrientos V, Alzamora R, Hevia D, Morales C, Pinto M, Escudero N, García L, Novoa U, et al. (2014) Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. J Hypertens 32:771-783.
225. O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, et al. (2011) Effect of nesiritide in patients with acute decompensated heart failure [published correction appears in N Engl J Med (2011) 365:773]. N Engl J Med 365:32-43.
226. Oefner C, D’Arcy A, Hennig M, Winkler FK, and Dale GE (2000) Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon. J Mol Biol 296:341-349.
227. Oefner C, Pierau S, Schulz H, and Dale GE (2007) Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV. Acta Crystallogr D Biol Crystallogr 63:975-981.
228. Oefner C, Roques BP, Fournie-Zaluski MC, and Dale GE (2004) Structural analysis of neprilysin with various specific and potent inhibitors. Acta Crystallogr D Biol Crystallogr 60:392-396.
229. Ohshima K, Mogi M, Nakaoka H, Iwanami J, Min LJ, Kanno H, Tsukuda K, Chisaka T, Bai HY, Wang XL, et al. (2014) Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension 63:e53-e59.
230. Okolicany J, McEnroe GA, Koh GY, Lewicki JA, and Maack T (1992) Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor. Am J Physiol 263:F546-F553.
231. Olearczyk J, Gao S, Eybye M, Yendluri S, Andrews L, Bartz S, Cully D, and Tadin-Strapps M (2014) Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension. Hypertens Res 37:405-412.
232. O’Neill HG, Redelinghuys P, Schwager SL, and Sturrock ED (2008) The role of glycosylation and domain interactions in the thermal stability of human angiotensinconverting enzyme. Biol Chem 389:1153-1161.
233. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, et al. (2018) Hypertension. Nat Rev Dis Primers 4:18014.
234. Oparil S and Schmieder RE (2015) New approaches in the treatment of hypertension. Circ Res 116:1074-1095.
235. Owens RE and Oliphant CS (2017) Angioedema spotlight: a closer examination of sacubitril/valsartan safety results. J Am Board Fam Med 30:556-557.
236. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, and Swedberg K (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106:920-926.
237. Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, and Zile MR (2018) Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol 6:547-554.
238. Packer M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, Pratt CM, Petrie MC, DeMets D, Kobrin I, et al.; ENABLE Investigators and Committees (2017) Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. JACC Heart Fail 5:317-326.
239. Page IH and Helmer OM (1940) A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. J Exp Med 71:29-42.
240. Pandey KN (2005) Biology of natriuretic peptides and their receptors. Peptides 26:901-932.
241. Papinska AM, Soto M, Meeks CJ, and Rodgers KE (2016) Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling. Pharmacol Res 107:372-380.
242. Patel VB, Zhong JC, Grant MB, and Oudit GY (2016) Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res 118:1313-1326.
243. Phillips MI (1987) Functions of angiotensin in the central nervous system. Annu Rev Physiol 49:413-435.
244. Pinheiro SVB, Simões e Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, Pesquero JB, Walther T, Alenina N, Bader M, et al. (2004) Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44:490-496.
245. Pinter M, Kwanten WJ, and Jain RK (2018) Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events. Clin Cancer Res 24:3803-3812.
246. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582-1587.
247. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, et al.; ESC Scientific Document Group (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC [published corrections appear in Eur Heart J (2018) 39:860, 1206]. Eur Heart J 37:2129-2200.
248. Potter LR (2011) Natriuretic peptide metabolism, clearance and degradation. FEBS J 278:1808-1817.
249. Pu Q, Touyz RM, and Schiffrin EL (2002) Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 20:899-907.
250. Pucell AG, Hodges JC, Sen I, Bumpus FM, and Husain A (1991) Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor. Endocrinology 128:1947-1959.
251. Rabey FM, Karamyan VT, and Speth RC (2010) Distribution of a novel binding site for angiotensins II and III in mouse tissues. Regul Pept 162:5-11.
252. Rabin M, Birnbaum D, Young D, Birchmeier C, Wigler M, and Ruddle FH (1987) Human ros1 and mas1 oncogenes located in regions of chromosome 6 associated with tumor-specific rearrangements. Oncogene Res 1:169-178.
253. Raine AE, Erne P, Bürgisser E, Müller FB, Bolli P, Burkart F, and Bühler FR (1986) Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 315:533-537.
254. Rajagopal S, Rajagopal K, and Lefkowitz RJ (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373-386.
255. Ravichandran K, Ozkok A, Wang Q, Mullick AE, and Edelstein CL (2015) Antisensemediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2. Am J Physiol Renal Physiol 308:F349-F357.
256. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, et al. (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 376:1430-1440.
257. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, Corvol P, and Llorens-Cortes C (1999) Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci USA 96:13415-13420.
258. Regoli D and Barabé J (1980) Pharmacology of bradykinin and related kinins. Pharmacol Rev 32:1-46.
259. Ren L, Sun Y, Lu H, Ye D, Han L, Wang N, Daugherty A, Li F, Wang M, and Su F (2018) (Pro)renin receptor inhibition reprograms hepatic lipid metabolism and protects mice from diet-induced obesity and hepatosteatosis. Circ Res 122:730-741.
260. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, and Hooper NM (2006) Circulating activities of angiotensin-converting enzyme, its homolog, angiotensinconverting enzyme 2, and neprilysin in a family study. Hypertension 48:914-920.
261. Rice GI, Thomas DA, Grant PJ, Turner AJ, and Hooper NM (2004) Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383:45-51.
262. Robl JA, Sieber-McMaster E, Asaad MM, Bird JE, Delaney NG, Barrish JC, Neubeck R, Natarajan S, Cohen M, and Rovnyak GC (1994) Mercaptoacyl dipeptides as dual inhibitors of angiotensin converting enzyme and neutral peptidase. Preliminary structure-activity studies. Bioorg Med Chem Lett 4:1783-1789.
263. Robl JA, Sulsky R, Sieber-McMaster E, Ryono DE, Cimarusti MP, Simpkins LM, Karanewsky DS, Chao S, Asaad MM, Seymour AA, et al. (1999) Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides. J Med Chem 42:305-311.
264. Robl JA, Sun CQ, Stevenson J, Ryono DE, Simpkins LM, Cimarusti MP, Dejneka T, Slusarchyk WA, Chao S, Stratton L, et al. (1997) Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 40:1570-1577.
265. Rodgers KE, Bolton LL, Verco S, and diZerega GS (2015) NorLeu3-angiotensin (1-7) [DSC127] as a therapy for the healing of diabetic foot ulcers. Adv Wound Care (New Rochelle) 4:339-345.
266. Roksnoer LC, Heijnen BF, Nakano D, Peti-Peterdi J, Walsh SB, Garrelds IM, van Gool JM, Zietse R, Struijker-Boudier HA, Hoorn EJ, et al. (2016a) On the origin of urinary renin: a translational approach. Hypertension 67:927-933.
267. Roksnoer LC, van Veghel R, de Vries R, Garrelds IM, Bhaggoe UM, Friesema EC, Leijten FP, Poglitsch M, Domenig O, Clahsen-van Groningen MC, et al. (2015) Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. Kidney Int 88:109-120.
268. Roksnoer LC, van Veghel R, van Groningen MC, de Vries R, Garrelds IM, Bhaggoe UM, van Gool JM, Friesema EC, Leijten FP, Hoorn EJ, et al. (2016b) Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptorneprilysin inhibition compared with AT1 receptor blockade alone. Clin Sci (Lond) 130:1209-1220.
269. Roques BP, Fournié-Zaluski MC, Soroca E, Lecomte JM, Malfroy B, Llorens C, and Schwartz JC (1980) The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 288:286-288.
270. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, and Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87-146.
271. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, et al.; American Heart Association; American College of Cardiology; American Society of Hypertension (2015) Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol 65:1998-2038.
272. Røsjø H, Dahl MB, Jørgensen M, Røysland R, Brynildsen J, Cataliotti A, Christensen G, Høiseth AD, Hagve TA, and Omland T (2015) Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study. Clin Chem 61:1087-1097.
273. Rossi GP, Sacchetto A, Cesari M, and Pessina AC (1999) Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 43:300-307.
274. Rozenfeld R, Iturrioz X, Maigret B, and Llorens-Cortes C (2002) Contribution of molecular modeling and site-directed mutagenesis to the identification of two structural residues, Arg-220 and Asp-227, in aminopeptidase A. J Biol Chem 277:29242-29252.
275. Rozenfeld R, Iturrioz X, Okada M, Maigret B, and Llorens-Cortes C (2003) Contribution of molecular modeling and site-directed mutagenesis to the identification of a new residue, glutamate 215, involved in the exopeptidase specificity of aminopeptidase A. Biochemistry 42:14785-14793.
276. Rubanyi GM and Polokoff MA (1994) Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46:325-415.
277. Rubattu S, Cotugno M, Forte M, Stanzione R, Bianchi F, Madonna M, Marchitti S, and Volpe M (2018) Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat. J Hypertens 36:1902-1914.
278. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, and Lefkowitz MP (2010) Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375:1255-1266.
279. Russell FD and Davenport AP (1999) Secretory pathways in endothelin synthesis. Br J Pharmacol 126:391-398.
280. Sahli S, Frank B, Schweizer WB, Diederich F, Blum-Kaelin D, Aebi JD, Böhm H, Oefner C, and Dale GE (2005) Second-generation inhibitors for the metalloprotease neprilysin based on bicyclic heteroaromatic scaffolds: synthesis, biological activity, and X-ray crystal-structure analysis. Helv Chim Acta 88:731-750.
281. Sakai K and Sigmund CD (2005) Molecular evidence of tissue renin-angiotensin systems: a focus on the brain. Curr Hypertens Rep 7:135-140.
282. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, and Touyz RM (2007) Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49:185-192.
283. Sandberg K, Ji H, Clark AJ, Shapira H, and Catt KJ (1992) Cloning and expression of a novel angiotensin II receptor subtype. J Biol Chem 267:9455-9458.
284. Santos RA, Campagnole-Santos MJ, Baracho NC, Fontes MA, Silva LC, Neves LA, Oliveira DR, Caligiorne SM, Rodrigues AR, Gropen Júnior C, et al. (1994) Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull 35:293-298.
285. Santos RA, Ferreira AJ, Verano-Braga T, and Bader M (2013) Angiotensinconverting enzyme 2, angiotensin-(1-7) and Mas: new players of the reninangiotensin system. J Endocrinol 216:R1-R17.
286. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100:8258-8263.
287. Santos RAS, Oudit GY, Verano-Braga T, Canta G, Steckelings UM, and Bader M (2019) The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol 316:H958-H970.
288. Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, and Campagnole-Santos MJ (2018) The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev 98:505-553.
289. Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, and Inagami T (1991) Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 351:230-233.
290. Sauer AJ, Cole R, Jensen BC, Pal J, Sharma N, Yehya A, and Vader J (2019) Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev 24:167-176.
291. Savage PD, Lovato J, Brosnihan KB, Miller AA, and Petty WJ (2016) Phase II trial of angiotensin-(1-7) for the treatment of patients with metastatic sarcoma. Sarcoma 2016:4592768.
292. Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, Costa-Fraga FP, Fraga-Silva RA, Cojocaru G, Cohen Y, et al. (2010) Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 56:112-120.
293. Savergnini SQ, Ianzer D, Carvalho MB, Ferreira AJ, Silva GA, Marques FD, Peluso AAB, Beiman M, Cojocaru G, Cohen Y, et al. (2013) The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. PLoS One 8:e57757.
294. Schechter I and Berger A (1967) On the size of active proteases. I. Papain. Biochem Biophys Res Commun 27:157-162.
295. Schiering N, D’Arcy A, Villard F, Ramage P, Logel C, Cumin F, Ksander GM, Wiesmann C, Karki RG, and Mogi M (2016) Structure of neprilysin in complex with the active metabolite of sacubitril. Sci Rep 6:27909.
296. Schulz H, Dale GE, Karimi-Nejad Y, and Oefner C (2009) Structure of human endothelin-converting enzyme I complexed with phosphoramidon. J Mol Biol 385:178-187.
297. Schunkert H, Danser AH, Hense HW, Derkx FH, Kürzinger S, and Riegger GA (1997) Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 95:39-45.
298. Seguin LR, Villarreal RS, and Ciuffo GM (2012) AT2 receptors recruit c-Src, SHP-1 and FAK upon activation by Ang II in PND15 rat hindbrain. Neurochem Int 60:199-207.
299. Seymour AA, Swerdel JN, and Abboa-Offei B (1991) Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 17:456-465.
300. Sharp S, Poglitsch M, Zilla P, Davies NH, and Sturrock ED (2015) Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats. J Renin Angiotensin Aldosterone Syst 16:1149-1158.
301. Shemesh R, Toporik A, Levine Z, Hecht I, Rotman G, Wool A, Dahary D, Gofer E, Kliger Y, Soffer MA, et al. (2008) Discovery and validation of novel peptide agonists for G-protein-coupled receptors. J Biol Chem 283:34643-34649.
302. Shenoy V, Kwon KC, Rathinasabapathy A, Lin S, Jin G, Song C, Shil P, Nair A, Qi Y, Li Q, et al. (2014) Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. Hypertension 64:1248-1259.
303. Shimada K, Furukawa H, Wada K, Wei Y, Tada Y, Kuwabara A, Shikata F, Kanematsu Y, Lawton MT, Kitazato KT, et al. (2015) Angiotensin-(1-7) protects against the development of aneurysmal subarachnoid hemorrhage in mice. J Cereb Blood Flow Metab 35:1163-1168.
304. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, et al. (2001) Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem 276:21895-21901.
305. Sigmund CD, Diz DI, and Chappell MC (2017) No brain renin-angiotensin system: déjà vu all over again? Hypertension 69:1007-1010.
306. Simon SR, Black HR, Moser M, and Berland WE (1992) Cough and ACE inhibitors. Arch Intern Med 152:1698-1700.
307. Skeggs LT Jr, Kahn JR, and Shumway NP (1956) The preparation and function of the hypertensin-converting enzyme. J Exp Med 103:295-299.
308. Skidgel RA, Engelbrecht S, Johnson AR, and Erdös EG (1984) Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 5:769-776.
309. Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, et al. (2017) Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail 5:471-482.
310. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, et al.; Prospective Comparison of ARNI with ARB on Management Of Heart Failure with Preserved Ejection Fraction (PARAMOUNT) Investigators (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380:1387-1395.
311. Song K, Allen AM, Paxinos G, and Mendelsohn FA (1992) Mapping of angiotensin II receptor subtype heterogeneity in rat brain. J Comp Neurol 316:467-484.
312. Soualmia H, Barthélemy C, Masson F, Maistre G, Eurin J, and Carayon A (1997) Angiotensin II-induced phosphoinositide production and atrial natriuretic peptide release in rat atrial tissue. J Cardiovasc Pharmacol 29:605-611.
313. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, and Corvol P (1988) Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 85:9386-9390.
314. Srivastava PK, Claggett BL, Solomon SD, McMurray JJV, Packer M, Zile MR, Desai AS, Rouleau JL, Swedberg K, and Fonarow GC (2018) Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial. JAMA Cardiol 3:1226-1231.
315. Stasch JP, Hirth-Dietrich C, Kazda S, and Neuser D (1989) Endothelin stimulates release of atrial natriuretic peptides in vitro and in vivo. Life Sci 45:869-875.
316. Steckelings UM, Artuc M, Wollschläger T, Wiehstutz S, and Henz BM (2001) Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol 81:321-325.
317. Steckelings UM, Kloet A, and Sumners C (2017) Centrally mediated cardiovascular actions of the angiotensin II type 2 receptor. Trends Endocrinol Metab 28:684-693.
318. Stone C Jr and Brown NJ (2017) Angiotensin-converting enzyme inhibitor and other drug-associated angioedema. Immunol Allergy Clin North Am 37:483-495.
319. Stragier B, Hristova I, Sarre S, Ebinger G, and Michotte Y (2005) In vivo characterization of the angiotensin-(1-7)-induced dopamine and g-aminobutyric acid release in the striatum of the rat. Eur J Neurosci 22:658-664.
320. Straka BT, Ramirez CE, Byrd JB, Stone E, Woodard-Grice A, Nian H, Yu C, Banerji A, and Brown NJ (2017) Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. J Allergy Clin Immunol 140:242-248.
321. Sturrock ED, Lubbe L, Cozier GE, Schwager SLU, Arowolo AT, Arendse LB, Belcher E, and Acharya KR (2019) Structural basis for the C-domain-selective angiotensinconverting enzyme inhibition by bradykinin-potentiating peptide b (BPPb). Biochem J 476 (10):1553-1570.
322. Sulpizio AC, Pullen MA, Edwards RM, Louttit JB, West R, and Brooks DP (2005) Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther 315:1306-1313.
323. Suwa M, Seino Y, Nomachi Y, Matsuki S, and Funahashi K (2005) Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy. Circ J 69:283-290.
324. Tabrizchi R (2001) Omapatrilat. Bristol-Myers Squibb. Curr Opin Investig Drugs 2:1414-1422.
325. Takahashi M, Matsushita Y, Iijima Y, and Tanzawa K (1993) Purification and characterization of endothelin-converting enzyme from rat lung. J Biol Chem 268:21394-21398.
326. Tallant EA, Ferrario CM, and Gallagher PE (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289:H1560-H1566.
327. Tamargo J, Duarte J, and Ruilope LM (2015) New antihypertensive drugs under development. Curr Med Chem 22:305-342.
328. Tetzner A, Gebolys K, Meinert C, Klein S, Uhlich A, Trebicka J, Villacañas Ó, and Walther T (2016) G-protein-coupled receptor MrgD is a receptor for angiotensin-(1-7) involving adenylyl cyclase, cAMP, and phosphokinase A. Hypertension 68:185-194.
329. Than A, Leow MK, and Chen P (2013) Control of adipogenesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways. J Biol Chem 288:15520-15531.
330. Thomas WG and Sernia C (1988) Immunocytochemical localization of angiotensinogen in the rat brain. Neuroscience 25:319-341.
331. Thunnissen MM, Nordlund P, and Haeggström JZ (2001) Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. Nat Struct Biol 8:131-135.
332. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, and Turner AJ (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275:33238-33243.
333. Tirupula KC, Desnoyer R, Speth RC, and Karnik SS (2014) Atypical signaling and functional desensitization response of MAS receptor to peptide ligands. PLoS One 9:e103520.
334. Tom B, de Vries R, Saxena PR, and Danser AHJ (2001) Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension 38:95-99.
335. Torrado J, Cain C, Mauro AG, Romeo F, Ockaili R, Chau VQ, Nestler JA, Devarakonda T, Ghosh S, Das A, et al. (2018) Sacubitril/valsartan averts adverse postinfarction ventricular remodeling and preserves systolic function in rabbits. J Am Coll Cardiol 72:2342-2356.
336. Tóth AD, Turu G, Hunyady L, and Balla A (2018) Novel mechanisms of G-proteincoupled receptors functions: AT1 angiotensin receptor acts as a signaling hub and focal point of receptor cross-talk. Best Pract Res Clin Endocrinol Metab 32:69-82.
337. Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, Ryan D, Fisher M, Williams D, Dales NA, et al. (2004) ACE2 X-ray structures reveal a large hingebending motion important for inhibitor binding and catalysis. J Biol Chem 279:17996-18007.
338. Trask AJ and Ferrario CM (2007) Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 25:162-174.
339. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, and Schaeffer TR (1998) Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 11:363-372.
340. Turcaud S, Gonzalez W, Michel J, Roques BP, and Fournie-Zaluski M (1995) Diastereoselective synthesis of mixanpril, an orally active dual inhibitor of neutral endopeptidase and angiotensin converting enzyme. Bioorg Med Chem Lett 5:1893-1898.
341. Turner AJ and Tanzawa K (1997) Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 11:355-364.
342. Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, de Vries R, Poglitsch M, Zlatev I, Kim JB, et al. (2019) Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen. Hypertension 73:1249-1257.
343. Uijl E, Ren L, and Danser AHJ (2018) Angiotensin generation in the brain: a reevaluation. Clin Sci (Lond) 132:839-850.
344. van Esch JH, Tom B, Dive V, Batenburg WW, Georgiadis D, Yiotakis A, van Gool JM, de Bruijn RJ, de Vries R, and Danser AH (2005) Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension 45:120-125.
345. van Thiel BS, Góes Martini A, Te Riet L, Severs D, Uijl E, Garrelds IM, Leijten FPJ, van der Pluijm I, Essers J, Qadri F, et al. (2017) Brain renin-angiotensin system: does it exist? Hypertension 69:1136-1144.
346. van Twist DJ, Kroon AA, and de Leeuw PW (2014) Angiotensin-(1-7) as a strategy in the treatment of hypertension? Curr Opin Nephrol Hypertens 23:480-486.
347. van’t Veer LJ, van der Feltz MJ, van den Berg-Bakker CA, Cheng NC, Hermens RP, van Oorschot DA, Kievits T, and Schrier PI (1993) Activation of the mas oncogene involves coupling to human alphoid sequences. Oncogene 8:2673-2681.
348. Vardeny O, Miller R, and Solomon SD (2014) Combined neprilysin and reninangiotensin system inhibition for the treatment of heart failure. JACC Heart Fail 2:663-670.
349. Vazeux G, Iturrioz X, Corvol P, and Llorens-Cortès C (1997) A tyrosine residue essential for catalytic activity in aminopeptidase A. Biochem J 327:883-889.
350. Vazeux G, Iturrioz X, Corvol P, and Llorens-Cortes C (1998) A glutamate residue contributes to the exopeptidase specificity in aminopeptidase A. Biochem J 334:407-413.
351. Vazeux G, Wang J, Corvol P, and Llorens-Cortès C (1996) Identification of glutamate residues essential for catalytic activity and zinc coordination in aminopeptidase A. J Biol Chem 271:9069-9074.
352. Veerasingham SJ and Raizada MK (2003) Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives. Br J Pharmacol 139:191-202.
353. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, and Braunwald E; PIONEER-HF Investigators (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380:539-548.
354. Verdonk K, Saleh L, Lankhorst S, Smilde JE, van Ingen MM, Garrelds IM, Friesema EC, Russcher H, van den Meiracker AH, Visser W, et al. (2015) Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension 65:1316-1323.
355. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, et al. (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277:14838-14843.
356. Vijayaraghavan J, Scicli AG, Carretero OA, Slaughter C, Moomaw C, and Hersh LB (1990) The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem 265:14150-14155.
357. Villar IC, Panayiotou CM, Sheraz A, Madhani M, Scotland RS, Nobles M, Kemp-Harper B, Ahluwalia A, and Hobbs AJ (2007) Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor. Cardiovasc Res 74:515-525.
358. Vodovar N, Séronde MF, Laribi S, Gayat E, Lassus J, Januzzi JL Jr, Boukef R, Nouira S, Manivet P, Samuel JL, et al. GREAT Network (2015) Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC Heart Fail 3:629-636.
359. Walters PE, Gaspari TA, and Widdop RE (2005) Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 45:960-966.
360. Wang J and Cooper MD (1993) Histidine residue in the zinc-binding motif of aminopeptidase A is critical for enzymatic activity. Proc Natl Acad Sci USA 90:1222-1226.
361. Watermeyer JM, Kröger WL, O’Neill HG, Sewell BT, and Sturrock ED (2008) Probing the basis of domain-dependent inhibition using novel ketone inhibitors of angiotensin-converting enzyme. Biochemistry 47:5942-5950.
362. Watermeyer JM, Kröger WL, O’Neill HG, Sewell BT, and Sturrock ED (2010) Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem J 428:67-74.
363. Watts JK and Corey DR (2012) Silencing disease genes in the laboratory and the clinic. J Pathol 226:365-379.
364. Weber MA (2001) Vasopeptidase inhibitors. Lancet 358:1525-1532.
365. Weber MA and Messerli FH (2008) Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 51:1465-1467.
366. Wei A, Gu Z, Li J, Liu X, Wu X, Han Y, and Pu J (2016) Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J Am Heart Assoc 5:e003896.
367. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CG, Edwards WD, Schaff HV, and Burnett JC Jr (1993) Natriuretic peptide system in human heart failure. Circulation 88:1004-1009.
368. Wei L, Clauser E, Alhenc-Gelas F, and Corvol P (1992) The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 267:13398-13405.
369. Welches WR, Brosnihan KB, and Ferrario CM (1993) A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 52:1461-1480.
370. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in J Am Coll Cardiol (2018) 71:2275-2279]. J Am Coll Cardiol 71:e127-e248.
371. Wielbo D, Sernia C, Gyurko R, and Phillips MI (1995) Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 25:314-319.
372. Wiemer G, Dobrucki LW, Louka FR, Malinski T, and Heitsch H (2002) AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 40:847-852.
373. Williams TA, Corvol P, and Soubrier F (1994) Identification of two active site residues in human angiotensin I-converting enzyme. J Biol Chem 269:29430-29434.
374. Woodman ZL, Oppong SY, Cook S, Hooper NM, Schwager SL, Brandt WF, Ehlers MR, and Sturrock ED (2000) Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites. Biochem J 347:711-718.
375. Wright JM, Musini VM, and Gill R (2018) First-line drugs for hypertension. Cochrane Database Syst Rev 4:CD001841.
376. Wright JW and Harding JW (1995) Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Regul Pept 59:269-295.
377. Wright JW and Harding JW (1997) Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res Brain Res Rev 25:96-124.
378. Wright JW, Miller-Wing AV, Shaffer MJ, Higginson C, Wright DE, Hanesworth JM, and Harding JW (1993) Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory. Brain Res Bull 32:497-502.
379. Wright JW, Tamura-Myers E, Wilson WL, Roques BP, Llorens-Cortes C, Speth RC, and Harding JW (2003) Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats. Am J Physiol Regul Integr Comp Physiol 284: R725-R733.
380. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, and Yanagisawa M (1994) ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78:473-485.
381. Yamada T, Horiuchi M, and Dzau VJ (1996) Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 93:156-160.
382. Yanagisawa M, Inoue A, Ishikawa T, Kasuya Y, Kimura S, Kumagaye S, Nakajima K, Watanabe TX, Sakakibara S, Goto K, et al. (1988) Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci USA 85:6964-6967.
383. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, et al. (2016) 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America [published correction appears in J Am Coll Cardiol (2016) 68:1495]. J Am Coll Cardiol 68:1476-1488.
384. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, et al. (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70:776-803.
385. Yandrapalli S, Khan MH, Rochlani Y, and Aronow WS (2018) Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. Ther Adv Cardiovasc Dis 12:217-231.
386. Yang Y, Liu C, Lin YL, and Li F (2013) Structural insights into central hypertension regulation by human aminopeptidase A. J Biol Chem 288:25638-25645.
387. Ye F, Wang Y, Wu C, Howatt DA, Wu CH, Balakrishnan A, Mullick AE, Graham MJ, Danser AHJ, Wang J, et al. (2019) Angiotensinogen and megalin interactions contribute to atherosclerosis-brief report. Arterioscler Thromb Vasc Biol 39:150-155.
388. Young D, Waitches G, Birchmeier C, Fasano O, and Wigler M (1986) Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 45:711-719.
389. Yu L, Yuan K, Phuong HTA, Park BM, and Kim SH (2016) Angiotensin-(1-5), an active mediator of renin-angiotensin system, stimulates ANP secretion via Mas receptor. Peptides 86:33-41.
390. Yu L, Zheng M, Wang W, Rozanski GJ, Zucker IH, and Gao L (2010) Developmental changes in AT1 and AT2 receptor-protein expression in rats. J Renin Angiotensin Aldosterone Syst 11:214-221.
391. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, and Anderson C; ONTARGET Investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-1559.
392. Zanchi A, Maillard M, and Burnier M (2003) Recent clinical trials with omapatrilat: new developments. Curr Hypertens Rep 5:346-352.
393. Zhang H, Han GW, Batyuk A, Ishchenko A, White KL, Patel N, Sadybekov A, Zamlynny B, Rudd MT, Hollenstein K, et al. (2017) Structural basis for selectivity and diversity in angiotensin II receptors. Nature 544:327-332.
394. Zhang H, Unal H, Gati C, Han GW, Liu W, Zatsepin NA, James D, Wang D, Nelson G, Weierstall U, et al. (2015) Structure of the angiotensin receptor revealed by serial femtosecond crystallography. Cell 161:833-844.
395. Zhang T, Li Z, Dang H, Chen R, Liaw C, Tran TA, Boatman PD, Connolly DT, and Adams JW (2012) Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am J Physiol Heart Circ Physiol 302:H299-H311.
396. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, and Llorens-Cortes C (1996) Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci USA 93:11968-11973.
397. Zini S, Masdehors P, Lenkei Z, Fournie-Zaluski MC, Roques BP, Corvol P, and Llorens-Cortes C (1997) Aminopeptidase A: distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats. Neuroscience 78:1187-1193.